RespiDART: Frontiers in Drug Development against Respiratory Viruses

Project Details

Description

Abstract /Project summary Over the past several decades, the DART conference series have focused on the latest developments in antiviral therapy against viruses such as HIV, hepatitis B and hepatitis C. Just as viruses are ever evolving, the DART series strives to adapt itself to emerging challenges facing today?s global community. Respiratory viruses such as RSV and influenza virus have longed threatened human health, especially in vulnerable populations such as infants, the elderly, and the immune-compromised. Recent outbreaks of emerging threats such as MERS-CoV, parainfluenza virus and metapneumovirus have raised alarm across the globe. By bringing together world leaders and key opinion holders, RespiDART 2018 will tackle current challenges in vaccine and drug development against respiratory viruses. Specific Aims: 1. Provide an interactive workshop setting where clinicians, basic scientists and health care workers can share and discuss the latest medical and scientific developments in the field of therapeutics development against respiratory viruses; 2. Develop a cross-disciplinary program that facilitates the neutral and balanced exchange of scientific knowledge in the areas of biology, chemistry, pharmacology, clinical research and public health as related to topics such as epidemiology and barriers to treatment, vaccine development, and recent clinical advances of small molecules; 3. Enhance the training of young scientists such as graduate students and post- doctoral fellows and provide increased opportunities for underrepresented scientists and health care workers through attendee scholarships in a CME accredited setting. Educational Objectives: 1. Epidemiology, screening & diagnosis for respiratory viruses; 2. Pediatric, geriatric and special populations considerations and barriers to treatment; 3. New antiviral targets and novel therapeutics in development; 4. Current status of antiviral and vaccines in clinical trials; 5. Enzymology, immunology, host-virus interactions, and virus replication; 6. Animal and cell culture models for development of therapeutics against respiratory viruses; 7. Drug resistance, vaccine resistance, and viral evolution. Design & Methods: RespiDART 2018 will take place in Miami, Florida over a 1.5 days period, at a location that is easily accessed by both national and international delegates. The program will include state-of-the-art lectures, oral abstract presentations, discussion panels and a poster session. This ACCME-accredited program will provide ample time for formal and informal networking and discussion amongst the delegates during the poster session and meal breaks.
StatusFinished
Effective start/end date1/11/1831/10/19

Funding

  • National Institute of Allergy and Infectious Diseases: $5,000.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.